Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

850 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin.
Goel R, Chouinard E, Stewart DJ, Huan S, Hirte H, Stafford S, Waterfield B, Roach J, Lathia C, Agarwal V, Humphrey R, Walsh W, Matthews S, Seymour L. Goel R, et al. Among authors: walsh w. Invest New Drugs. 2005 Jan;23(1):63-71. doi: 10.1023/B:DRUG.0000047107.35764.d9. Invest New Drugs. 2005. PMID: 15528982 Clinical Trial.
A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
Goss G, Hirte H, Miller WH Jr, Lorimer IA, Stewart D, Batist G, Parolin DA, Hanna P, Stafford S, Friedmann J, Walsh W, Mathews S, Douglas L, Seymour LK. Goss G, et al. Among authors: walsh w. Invest New Drugs. 2005 Mar;23(2):147-55. doi: 10.1007/s10637-005-5860-y. Invest New Drugs. 2005. PMID: 15744591 Clinical Trial.
A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131.
Gelmon KA, Stewart D, Chi KN, Chia S, Cripps C, Huan S, Janke S, Ayers D, Fry D, Shabbits JA, Walsh W, McIntosh L, Seymour LK. Gelmon KA, et al. Among authors: walsh w. Ann Oncol. 2004 Jul;15(7):1115-22. doi: 10.1093/annonc/mdh278. Ann Oncol. 2004. PMID: 15205207 Free article. Clinical Trial.
Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group.
Laurie SA, Gauthier I, Arnold A, Shepherd FA, Ellis PM, Chen E, Goss G, Powers J, Walsh W, Tu D, Robertson J, Puchalski TA, Seymour L. Laurie SA, et al. Among authors: walsh w. J Clin Oncol. 2008 Apr 10;26(11):1871-8. doi: 10.1200/JCO.2007.14.4741. J Clin Oncol. 2008. PMID: 18398152 Clinical Trial.
A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
Goss G, Siu LL, Gauthier I, Chen EX, Oza AM, Goel R, Maroun J, Powers J, Walsh W, Maclean M, Drolet DW, Rusk J, Seymour LK; Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group. Goss G, et al. Among authors: walsh w. Cancer Chemother Pharmacol. 2006 Nov;58(5):703-10. doi: 10.1007/s00280-006-0201-1. Epub 2006 Mar 10. Cancer Chemother Pharmacol. 2006. PMID: 16528532 Clinical Trial.
850 results